- Home
- BLRX vs CLDI Comparison
BLRX vs CLDI Comparison
Compare BLRX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CLDI
- Stock Information
- Founded
- BLRX 2003
- CLDI 2014
- Country
- BLRX Israel
- CLDI United States
- Employees
- BLRX N/A
- CLDI N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLRX Health Care
- CLDI Health Care
- Exchange
- BLRX Nasdaq
- CLDI Nasdaq
- Market Cap
- BLRX 17.3M
- CLDI 18.1M
- IPO Year
- BLRX 2011
- CLDI N/A
- Fundamental
- Price
- BLRX $0.10
- CLDI $0.89
- Analyst Decision
- BLRX Strong Buy
- CLDI Strong Buy
- Analyst Count
- BLRX 2
- CLDI 3
- Target Price
- BLRX $5.50
- CLDI $16.67
- AVG Volume (30 Days)
- BLRX 18.8M
- CLDI 1.2M
- Earning Date
- BLRX 11-25-2024
- CLDI 03-14-2025
- Dividend Yield
- BLRX N/A
- CLDI N/A
- EPS Growth
- BLRX N/A
- CLDI N/A
- EPS
- BLRX N/A
- CLDI N/A
- Revenue
- BLRX $21,991,000.00
- CLDI N/A
- Revenue This Year
- BLRX N/A
- CLDI N/A
- Revenue Next Year
- BLRX N/A
- CLDI N/A
- P/E Ratio
- BLRX N/A
- CLDI N/A
- Revenue Growth
- BLRX N/A
- CLDI N/A
- 52 Week Low
- BLRX $0.08
- CLDI $0.73
- 52 Week High
- BLRX $1.44
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- BLRX 28.83
- CLDI 32.62
- Support Level
- BLRX $0.23
- CLDI $0.83
- Resistance Level
- BLRX $0.14
- CLDI $0.95
- Average True Range (ATR)
- BLRX 0.03
- CLDI 0.12
- MACD
- BLRX -0.00
- CLDI -0.03
- Stochastic Oscillator
- BLRX 6.93
- CLDI 11.29
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.